CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction

Recruiting Phase 4 Interventional Study
Atrial Fibrillation Heart Failure With Preserved Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
1,548 (estimated)
Sponsor
Charite University, Berlin, Germany · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
INCLUSION CRITERIA: 1. Age ≥18 years 2. Signed written informed consent 3. Clinical evidence of symptomatic heart failure (NYHA Class II-III) 4. Paroxysmal or persistent atrial fibrillation (less than 24 months after first diagnosis, documented at least on one 12-lead ECG) 5. Left ventricular eject…
Contacts

Abdul Parwani, Dr.

+4930450565383

caba_hfpef@charite.de

CONTACT